Cilcare
Celia Belline is an experienced professional currently serving as a Foreign Trade Advisor at Les Conseillers du Commerce extérieur de la France and as an Ambassador for Team France Export at Business France. Since co-founding CILcare in 2014, Celia has led the biotech company in advancing auditory sciences and developing therapies for neurocognitive disorders. Prior to their ventures in biotechnology, Celia held significant roles at Sanofi, including Project Leader for Healthy Aging and Director of Global Supply Chain Management, where management of international teams and involvement in clinical trial design were key responsibilities. Celia's educational background includes specialized talent development programs at London Business School and ESSEC Business School, as well as a Master's degree in Pharmaceutical Drug Development from the University of Montpellier.
This person is not in any teams
Cilcare
CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases. CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus. CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy. CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring. We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.